Crossmark

PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy

Crossref DOI link: https://doi.org/10.1136/jitc-2024-011145

Published Online: 2025-05-07

Published Print: 2025-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Moseman, Jena E https://orcid.org/0000-0001-6849-3225
Rastogi, Ichwaku https://orcid.org/0000-0003-1957-1164
Jeon, Donghwan

McNeel, Douglas G https://orcid.org/0000-0003-1471-6723
Funding

Funding for this research was provided by:

NIH / NCI (P50 CA269011)

NIH / NCI (R01 CA219154)

NIH / NCI (T32 CA009135)
License Information

License valid from 2025-05-08